Breaking News, Collaborations & Alliances

SGS Quay Pharma Partners with Liveome to Develop & Commercialize LIV001

LIV001 is a candidate for the treatment of inflammatory bowel disease.

Author Image

By: Charlie Sternberg

Associate Editor

Contract development and manufacturing organization (CDMO) SGS Quay Pharma has signed a contract with Korean drug development specialist Liveome for the formulation development and clinical manufacture of a targeted release formulation for the treatment of inflammatory bowel disease containing lyophilized microbial cells suitable for phase one clinical trials. The drug substance is being supplied by Australia-based Luina Bio.   “Starting with these CDMO contracts for LIV001, we plan to build a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters